[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

TABLE OF CONTENTS

1          Introduction

1.1        Market Definition

1.2        Market Scope

2           Research Methodology

2.1        Primary Research

2.2        Research Methodology

2.3        Assumptions & Exclusions

2.4        Secondary Data Sources

3           Market Overview

3.1        Report Segmentation & Scope

3.2        Value Chain Analysis: Anti-Osteoporosis Therapy and Fracture Healing Market

3.3        Key Market Trends

3.3.1      Drivers

3.3.2      Restraints

3.3.3      Opportunities

3.4        Porter’s Five Forces Analysis

3.4.1      Bargaining Power of Suppliers

3.4.2      Bargaining Power of Buyers

3.4.3      Threat of Substitution

3.4.4      Threat of New Entrants

3.4.5      Competitive Rivalry

3.5       Market Share Analysis

4           By Route of Administration

4.1       Introduction

             4.1.1    Market Size & Forecast (Value)

4.2        Introduction

4.3        Injectable

5.          By Drug Type    

5.1        Introduction

5.1.1    Market Size & Forecast (Value)

5.2        Bisphosphonates 

5.3        Selective Oestrogen Receptor Modules

6           By Regional Overview  

6.1        Introduction      

6.1.1      Market Size & Forecast (Value) 

6.2       America              

6.2.1    North America  

6.2.1.1   U.S.       

6.2.1.1.1               By Route of Administration         

6.2.1.1.2               By Drug Type   

6.2.1.2   Canada

6.2.1.2.1                 By Route of Administration       

6.2.1.1.2               By Drug Type   

6.2.1.3   Mexico

6.2.1.3.1               By Route of Administration         

6.2.1.1.2               By Drug Type   

6.2.4      Latin America   

6.2.4.1                   By Route of Administration

6.2.4.2                  By Drug Type

6.3         Europe

6.3.1    Market Size & Forecast (Value) 

6.3.2    Germany            

6.3.2.1   By Route of Administration         

6.3.2.2   By Drug Type     

6.3.3    France 

6.3.3.1   By Route of Administration         

6.3.3.2   By Drug Type     

6.3.4    U.K        

6.3.4.1 By Route of Administration         

6.3.4.2 By Drug Type     

6.3.5    Italy      

6.3.5.1   By Route of Administration         

6.3.5.2   By Drug Type     

6.3.6    Spain    

6.3.6.1   By Route of Administration         

6.3.6.2   By Drug Type     

6.3.7      Rest of Europe 

6.3.7.1 By Route of Administration

6.3.7.2 By Drug Type

6.4         Asia Pacific         

6.4.1    Market Size & Forecast (Value) 

6.4.2    Japan   

6.4.2.1 By Route of Administration

6.4.2.2 By Drug Type     

6.4.3    China    

6.4.3.1 By Route of Administration

6.4.3.2 By Drug Type

6.4.4    Australia             

6.4.4.1 By Route of Administration         

6.4.4.2 By Drug Type     

6.4.5    India     

6.4.5.1 By Route of Administration         

6.4.5.2 By Drug Type     

6.4.6    South Korea      

6.4.6.1 By Route of Administration         

6.4.6.2 By Drug Type     

6.4.7    Rest of Asia-Pacific         

6.4.7.1 By Route of Administration         

6.4.7.2 By Drug Type     

6.5       Middle East & Africa      

6.5.1      Market Size & Forecast (Value) 

6.5.2      Saudi Arabia      

6.5.2.1 By Route of Administration         

6.5.2.2 By Drug Type     

6.5.3    South Africa       

6.5.3.1 By Route of Administration         

6.5.5.2 By Drug Type     

6.5.4    Kuwait 

6.5.4.1 By Route of Administration         

6.5.5.2 By Drug Type     

6.5.5    Rest of Middle East & Africa       

6.5.5.1 By Route of Administration         

6.5.5.2 By Drug Type     

7.         Company Profile                            

7.1       Hoffmann-La Roche Ltd

7.1.1    Company Overview       

7.1.2    Financial Performance  

7.1.3    Recent Developments  

7.1.4    Product Portfolio             

7.2       Actavis plc

7.2.1    Company Overview       

7.2.2    Financial Performance  

7.2.3    Recent Developments  

7.2.4    Product Portfolio             

7.3       Eli Lilly and Company

7.3.1    Company Overview       

7.3.2    Financial Performance  

7.3.3    Recent Developments  

7.3.4    Product Portfolio             

7.4       Teva Pharmaceutical Industries Ltd.

7.4.1    Company Overview       

7.4.2    Financial Performance  

7.4.3    Recent Developments  

7.4.4    Product Portfolio             

7.5       Merck and Company Inc.

7.5.1    Company Overview       

7.5.2    Financial Performance  

7.5.3    Recent Developments  

7.5.4    Product Portfolio             

7.6       Amgen Inc.

7.6.1    Company Overview       

7.6.2    Financial Performance  

7.6.3    Recent Developments  

7.6.4    Product Portfolio             

7.7       Novartis International AG.

7.7.1    Company Overview       

7.7.2    Financial Performance  

7.7.3    Recent Developments  

7.7.4    Product Portfolio

7.8       Pfizer, Inc.

7.8.1    Company Overview       

7.8.2    Financial Performance  

7.8.3    Recent Developments  

7.8.4    Product Portfolio

7.9       GlaxoSmithKline plc.

7.9.1    Company Overview       

7.9.2    Financial Performance  

7.9.3    Recent Developments 

7.9.4    Product Portfolio



Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports